SAPT After TAVR Linked to Key Benefits over DAPT, New Data Confirm

Why It Matters

The findings confirm that SAPT provides a safer, mortality‑saving antithrombotic strategy, reinforcing guideline shifts and potentially lowering overall healthcare costs.

Key Takeaways

• SAPT cut six‑month mortality to 2.4% vs 5.4% with DAPT
• 24‑month death rates: 11.7% SAPT vs 14.2% DAPT
• Major bleeding lower under SAPT; ischemic stroke unchanged
• DAPT use fell from 48% to 38% during study
• Results reinforce guidelines favoring SAPT after TAVR

Pulse Analysis

The optimal antithrombotic regimen after transcatheter aortic valve replacement (TAVR) has been a moving target for cardiologists. Early trials favored dual antiplatelet therapy (DAPT) to guard against valve thrombosis, but the accompanying rise in major bleeding prompted societies to reconsider. Recent guideline revisions already lean toward single antiplatelet therapy (SAPT) for patients without a separate indication for anticoagulation, yet real‑world evidence remained limited. Understanding how SAPT versus DAPT influences survival and safety is crucial as TAVR expands into lower‑risk and older populations worldwide.

The new analysis, published in JACC: Advances, pooled more than 5,000 TAVR recipients from five European countries between 2011 and 2023. Patients were a mean age of 81, half male, and free of chronic anticoagulation needs. At discharge, 58 % received SAPT (aspirin or clopidogrel) while 42 % were placed on DAPT. SAPT patients experienced a 2.4 % six‑month all‑cause mortality versus 5.4 % for DAPT, and 11.7 % versus 14.2 % at two years. Major bleeding was also reduced, with no rise in stroke or other ischemic events, and the benefit persisted across valve platforms and sexes.

These findings give clinicians robust data to favor SAPT, aligning practice with the observed mortality advantage and lower bleeding risk. Hospitals may see cost reductions from fewer transfusions and shorter stays, while patients benefit from a simpler medication regimen. The steady decline in DAPT use—from 48 % at the study’s start to 38 % by its end—reflects an evolving consensus that the incremental protection of DAPT does not outweigh its hazards. Future research should explore SAPT in high‑risk subgroups and assess long‑term valve durability, but the current evidence already supports updating institutional protocols and reinforcing guideline recommendations.